-The Hindu In a major boost to the country’s private vaccine manufacturing pharmaceutical companies, the World Health Organisation (WHO) has said that India’s national regulatory authority — Central Drugs Standard Control Organisation (CDSCO) — and its affiliated institutions meet the prescribed international standards. India is a major vaccine producer with 12 major vaccine manufacturing facilities. These vaccines are used for the national and international market, reaching nearly 150 countries. Every second child...

-Outlook Don’t blame globalization for inequality – but rather policies hijacked by a few Economic globalization in the sense of expansion of foreign trade and investment is, of course, somewhat anaemic, reflecting the impact of global recession, although still vigorous in the sense of continuous international transmission of technology, information, ideas and social media. But in the world of politics and policymaking a cold wind is blowing, dimming earlier enthusiasm for global...

-The Times of India A once-a-week medicine for diabetics — a disease that affects nearly 63 million Indians — could soon become a reality. Studies on diabetes have seen a global upsurge, with the latest data showing that bio-pharmaceutical research companies across the globe are busy developing 221 innovative new medicines. The drugs, which will help around 347 million patients include new therapies that target key abnormalities of pancreatic cells, increase insulin secretion...

-The Business Standard If the Cabinet clears the proposed policy, the Department of Pharmaceuticals would have to notify this before the SC?s next hearing on the matter on Nov 27 The Cabinet is likely to take up the proposed National Pharmaceutical Pricing Policy tomorrow, government sources said. The policy is aimed at capping the prices of 348 essential medicines at the weighted average of all drugs in a particular segment, with...

-The Business Standard The move is aimed at having a stringent regulatory system while bringing in uniformity in approach for pricing of drugs  The drug price regulator would now visit manufacturing facilities of pharmaceutical companies while fixing prices of essential medicines. The National Pharmaceutical Pricing Authority (NPPA) has issued internal guidelines putting in place norms for verification of actual cost data, provided by companies, through plant visits.  The move is aimed at...